This company listing is no longer active
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
TCR2 Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
TCR2 Therapeutics' CEO is Garry Menzel, appointed in Jan 2016, they has a tenure of 6.67 years. Their total yearly compensation is $1.90M , comprised of 30.4% salary and 69.6% bonuses, including company stock and options. They directly owns 0.69% of the company’s shares, worth €656.23K. The average tenure of the management team and the board of directors is 2 years and 3.1 years respectively.
Anahtar bilgiler
Garry Menzel
İcra Kurulu Başkanı
US$1.9m
Toplam tazminat
| CEO maaş yüzdesi | 30.4% |
| CEO görev süresi | 6.7yrs |
| CEO sahipliği | 0.7% |
| Yönetim ortalama görev süresi | 2yrs |
| Yönetim Kurulu ortalama görev süresi | 3.1yrs |
Son yönetim güncellemeleri
Recent updates
CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$115m |
| Mar 31 2022 | n/a | n/a | -US$107m |
| Dec 31 2021 | US$2m | US$580k | -US$100m |
| Sep 30 2021 | n/a | n/a | -US$91m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$73m |
| Dec 31 2020 | US$6m | US$560k | -US$67m |
| Sep 30 2020 | n/a | n/a | -US$61m |
| Jun 30 2020 | n/a | n/a | -US$58m |
| Mar 31 2020 | n/a | n/a | -US$53m |
| Dec 31 2019 | US$8m | US$492k | -US$97m |
| Sep 30 2019 | n/a | n/a | -US$96m |
| Jun 30 2019 | n/a | n/a | -US$100m |
| Mar 31 2019 | n/a | n/a | -US$107m |
| Dec 31 2018 | US$3m | US$436k | -US$62m |
| Sep 30 2018 | n/a | n/a | -US$55m |
| Dec 31 2017 | US$792k | US$423k | -US$15m |
Tazminat ve Piyasa: Garry's total compensation ($USD1.90M) is above average for companies of similar size in the German market ($USD410.59K).
Tazminat ve Kazançlar: Garry's compensation has been consistent with company performance over the past year.
CEO
Garry Menzel (58 yo)
6.7yrs
Görev süresi
US$1,904,534
Tazminat
Dr. Garry E. Menzel, Ph D., M.B.A. serves as an Independent Director at Black Diamond Therapeutics, Inc. since March 2017. He serves as Director at Stoke Therapeutics, Inc since August 17, 2020.He serves...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.7yrs | US$1.90m | 0.69% € 656.2k | |
| Founder & Member of the Advisory Board | no data | US$47.02k | Veri yok | |
| Chief Technical Officer | 1.2yrs | US$2.74m | 0.0057% € 5.4k | |
| Chief Medical Officer | 5.7yrs | US$1.04m | 0.12% € 116.0k | |
| Vice President of Corporate Controller | less than a year | Veri yok | Veri yok | |
| Chief Financial Officer | less than a year | Veri yok | Veri yok | |
| Senior Director of Investor Relations & Corporate Communications | no data | Veri yok | Veri yok | |
| Head of Legal & Corporate Secretary | 4.7yrs | Veri yok | Veri yok | |
| Chief People Officer | 2.9yrs | Veri yok | 0.025% € 24.0k | |
| Chief Business & Strategy Officer | less than a year | Veri yok | Veri yok |
2.0yrs
Ortalama Görev Süresi
48yo
Ortalama Yaş
Deneyimli Yönetim: 2K7's management team is considered experienced (2 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.7yrs | US$1.90m | 0.69% € 656.2k | |
| Founder & Member of the Advisory Board | less than a year | US$47.02k | Veri yok | |
| Independent Director | 7.3yrs | Veri yok | Veri yok | |
| Independent Director | 4.6yrs | US$92.52k | 0% € 0 | |
| Chairman of Advisory Board | no data | US$18.75k | Veri yok | |
| Independent Chairman of the Board | 2.3yrs | US$89.08k | 0% € 0 | |
| Independent Director | 3.8yrs | US$86.58k | 0% € 0 | |
| Independent Director | 2.4yrs | US$78.08k | 0% € 0 | |
| Independent Director | 1.6yrs | US$405.41k | 0% € 0 | |
| Member of Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Advisory Board | no data | Veri yok | Veri yok | |
| Member of Advisory Board | no data | Veri yok | Veri yok |
3.1yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 2K7's board of directors are considered experienced (3.1 years average tenure).